French drugmaker Sanofi (SNY) said that the U.S. would likely get its Covid-19 vaccine first once it is available.“The U.S. government has the right to the largest pre-order because it’s invested in taking the risk,” Sanofi CEO Paul Hudson said in an interview with Bloomberg News. The U.S., which expanded a vaccine partnership with the company in February, expects “that if we’ve helped you manufacture the doses at risk, we expect to get the doses first.”Hudson cautioned that Europe needs to step up efforts to find protection against the pandemic if it doesn’t want to fall behind.Last month Sanofi entered into a collaboration with GlaxoSmithKline (GSK) to jointly develop an adjuvanted vaccine for COVID-19. The two companies said they expected a candidate vaccine to enter Phase 1 clinical trials in the second half of 2020 and, if successful, they plan to make it available in the second half of 2021. The vaccine candidate is being supported through funding by the U.S. Biomedical Advanced Research and Development Authority (BARDA).While funding from the Biomedical Advanced Research and Development Authority puts the U.S. first in line, the country may be only days or weeks ahead of everyone else, Hudson said.“I’ve been campaigning in Europe to say the U.S. will get vaccines first,” Hudson said. “That’s how it will be because they’ve invested to try and protect their population, to restart their economy.”Sanofi also announced that it is in talks with the European Union and the French and German governments to accelerate regional vaccine development.Separately to its GSK collaboration, Sanofi’s vaccines division Sanofi Pasteur in March partnered with Translate Bio (TBIO) for the development of a messenger RNA (mRNA) vaccine against Covid-19.Shares in Sanofi were down 2.3% to $47.20 in pre-market U.S. trading. The stock has soared 27% in the past two months.TipRanks data shows that Goldman Sachs and Argus Research both have a Buy rating on the stock. The $56 price target set by Argus Research reflects 16% upside potential in the shares in the coming 12 months. (See Sanofi stock analysis on TipRanks).Related News: Gilead Signs Remdesivir Licensing Agreements With Five Drugmakers Allogene Explodes 28% After-Hours On Initial ALLO-501 Data Moderna’s COVID-19 Vaccine Candidate Progressing at ‘Warp Speed,’ Says Top Analyst More recent articles from Smarter Analyst: * 3 Biotech Stocks Under $4 With at Least 50% Upside Potential * Amazon Urges Congress to Establish a Law Against Price Gouging * Live Nation Announces $1.2B Debt Offering, Business Severely Affected by Covid-19 Crisis * GM Plans To Reopen Lucrative Mexican Pickup Plant Next Week- Report
from Yahoo Finance https://ift.tt/2WWbS9S
On Wednesday, Allogene (ALLO) revealed positive initial data from its ALLO-501 CD19 allogeneic CAR T, showing both activity and a tolerable safety profile. The news sent shares surging 28% in Wednesday’s after-hours trading.Allogene announced preliminary data from the Phase 1 dose escalation ALPHA trial of ALLO-501 in conjunction with the release of ASCO (American Society of Clinical Oncology) abstracts.As of the January cutoff, 3 non-Hodgkin lymphoma (NHL) patients achieved complete responses and 4 achieved partial responses, for an ORR [overall response rate] of 78% (n=7/9).“Although early, we believe these data suggest that ALLO-501 could go toe-to-toe with autologous CAR-Ts on performance and safety—setting a new bar for allogeneic CAR-Ts in NHL and underscoring the importance of Allogene’s antibody-dependent approach to lymphodepletion” commented Oppenheimer’s Mark Breidenbach following the report.He anticipates updated results from 11 evaluable patients in the May 29 oral presentation at ASCO—including patients treated with high-dose ALLO-647, which may further improve efficacy.As a result of these ‘encouraging early results’, Breidenbach reiterated his buy rating on the stock while ramping up his price target from $44 to $50 (61% upside potential).Meanwhile JP Morgan’s Cory Kasimov wrote: “In our view, this is good initial data but it hard to interpret relative to other CAR T / CD19 approaches given the limited details in the abstract (i.e. what doses, which histologies, and the amount of follow-up for patients still responding).”Ultimately, the JP Morgan analyst looks to the upcoming ASCO presentation (which will also include patients treated at a higher ‘647 dose) to further evaluate.ALLO currently shows a cautiously optimistic Moderate Buy consensus from the Street with 7 recent buy ratings vs 4 hold ratings. The average analyst price target stands at $34 (11% upside potential). (See ALLO stock analysis on TipRanks).Related News: Moderna’s COVID-19 Vaccine Candidate Progressing at ‘Warp Speed,’ Says Top Analyst Twilio Partners With Zocdoc For Telehealth Video Consultations CymaBay (CBAY) Stock Is up 127% in a Day. How Much Higher Can It Go? More recent articles from Smarter Analyst: * Amazon Urges Congress to Establish a Law Against Price Gouging * Live Nation Announces $1.2B Debt Offering, Business Severely Affected by Covid-19 Crisis * GM Plans To Reopen Lucrative Mexican Pickup Plant Next Week- Report * Cisco Shares Up Pre-Market After Topping Quarterly Profit Bets
For months, Tesla Chief Executive Elon Musk has been teasing investors, and rivals, with promises to reveal significant advances in battery technology during a “Battery Day” in late May. New, low-cost batteries designed to last for a million miles of use and enable electric Teslas to sell profitably for the same price or less than a gasoline vehicle are just part of Musk’s agenda, people familiar with the plans told Reuters.